https://ir.corbuspharma.com/ https://ir.corbuspharma.com/presentations https://ir.corbuspharma.com/analyst-coverage https://ir.corbuspharma.com/news-events/press-releases https://ir.corbuspharma.com/news-events/events https://ir.corbuspharma.com/company-information/profile https://ir.corbuspharma.com/company-information/ir-contacts https://ir.corbuspharma.com/company-information/faq https://ir.corbuspharma.com/financial-information/financial-results https://ir.corbuspharma.com/stock-data/quote-chart https://ir.corbuspharma.com/stock-data/historical-data https://ir.corbuspharma.com/sec-filings/all-sec-filings https://ir.corbuspharma.com/sec-filings/annual-reports https://ir.corbuspharma.com/sec-filings/quarterly-reports https://ir.corbuspharma.com/sec-filings/section-16-filings https://ir.corbuspharma.com/corporate-governance/board-of-directors https://ir.corbuspharma.com/corporate-governance/board-committees https://ir.corbuspharma.com/corporate-governance/governance-documents https://ir.corbuspharma.com/news-events/press-releases/detail/462/corbus-pharmaceuticals-to-participate-in-the-bmo-2026-metabolic-health-summit 2026-03-18T08:00:12-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/461/corbus-pharmaceuticals-reports-q4-and-2025-financial-results-and-provides-a-corporate-update 2026-03-09T07:30:02-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/460/corbus-pharmaceuticals-to-present-at-the-36th-annual-oppenheimer-healthcare-life-sciences-conference 2026-02-12T08:00:02-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/459/corbus-pharmaceuticals-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-05T07:30:02-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/458/corbus-pharmaceuticals-reports-results-from-phase-1a-study-of-oral-cb1-inverse-agonist-crb-913-for-the-treatment-for-obesity-demonstrating-favorable-safety-profile-and-emerging-evidence-of-weight-loss 2025-12-11T07:00:03-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/457/corbus-pharmaceuticals-to-report-results-from-phase-1a-study-of-oral-cb1-inverse-agonist-crb-913for-the-treatment-for-obesity-on-thursday-december-11-2025 2025-12-10T16:01:02-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/456/corbus-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides-a-corporate-update 2025-11-12T08:00:20-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/455/corbus-pharmaceuticals-to-participate-in-upcoming-investor-conferences 2025-11-06T08:00:39-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/454/corbus-pharmaceuticals-announces-pricing-of-public-offering 2025-10-31T02:40:25-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/453/corbus-pharmaceuticals-announces-proposed-public-offering 2025-10-30T16:31:37-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/452/corbus-pharmaceuticals-presents-crb-701-robust-clinical-responses-in-hnscc-and-cervical-cancers-at-esmo25 2025-10-18T04:14:21-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/451/corbus-pharmaceuticals-to-present-crb-701-phase-12-data-at-esmo-2025 2025-10-14T08:00:48-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/450/corbus-pharmaceuticals-to-participate-in-the-upcoming-piper-sandler-virtual-oncology-symposium 2025-10-07T08:00:27-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/449/corbus-pharmaceuticals-to-host-in-person-and-virtual-kol-event-at-esmo-2025 2025-09-22T08:00:05-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/448/fda-grants-fast-track-designation-to-corbus-pharmaceuticals-nectin-4-targeting-adc-crb-701-in-head-and-neck-squamous-cell-carcinoma 2025-09-16T08:00:31-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/447/corbus-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update 2025-08-05T08:00:23-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/446/corbus-pharmaceuticals-announces-upcoming-presentation-of-dose-expansion-phase-12-clinical-data-for-its-nectin-4-targeting-adc-crb-701-at-the-2025-esmo-annual-congress 2025-07-30T08:00:16-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/445/corbus-pharmaceuticals-initiates-multiple-ascending-dose-portion-of-phase-1-study-of-highly-peripherally-restricted-cb1-inverse-agonist-crb-913-for-the-treatment-of-obesity 2025-06-30T08:00:04-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/444/corbus-pharmaceuticals-announces-first-patient-dosed-with-its-nectin-4-targeting-adc-crb-701-in-combination-with-pembrolizumab 2025-06-25T08:00:13-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/443/corbus-pharmaceuticals-to-participate-in-the-3rd-annual-piper-obesity-symposium 2025-06-24T16:05:02-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/442/corbus-pharmaceuticals-to-present-at-the-jefferies-global-healthcare-conference 2025-05-22T08:00:09-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/441/corbus-pharmaceuticals-names-industry-veteran-rachelle-jacques-as-board-chair 2025-05-19T08:00:06-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/440/corbus-pharmaceuticals-to-present-at-the-2025-rbc-capital-markets-global-healthcare-conference 2025-05-08T08:00:22-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/439/corbus-pharmaceuticals-reports-first-quarter-2025-financial-results-and-provides-a-corporate-update 2025-05-06T08:00:22-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/438/corbus-pharmaceuticals-announces-first-patient-dosed-in-phase-1-clinical-study-of-next-generation-cb1-inverse-agonist-crb-913-for-the-treatment-of-obesity 2025-03-28T08:00:02-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/437/corbus-pharmaceuticals-reports-q4-and-2024-financial-results-and-provides-a-corporate-update 2025-03-11T08:00:32-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/436/corbus-pharmaceuticals-to-participate-in-upcoming-investor-conferences 2025-02-25T08:01:03-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/435/crb-701-sys6002-a-next-generation-nectin-4-targeting-adc-demonstrates-encouraging-safety-and-broader-efficacy-in-phase-1-study-in-the-us-and-uk-presented-at-asco-gu-2025 2025-02-14T07:30:01-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/434/corbus-pharmaceuticals-announces-clinical-data-for-crb-701-from-western-dose-escalation-study-to-be-presented-at-2025-asco-gu 2025-02-11T07:30:03-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/433/corbus-pharmaceuticals-to-present-at-the-guggenheim-smid-cap-biotech-conference 2025-01-28T08:00:31-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/432/corbus-pharmaceuticals-announces-that-clinical-data-for-crb-701-from-western-dose-escalation-study-to-be-presented-at-asco-gu-2025 2025-01-08T16:46:11-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/431/corbus-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-06T08:00:21-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/430/corbus-pharmaceuticals-announces-dosing-of-first-patient-in-its-first-in-human-study-of-crb-601-to-treat-patients-with-advanced-solid-tumors 2024-12-09T07:00:07-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/429/fda-grants-fast-track-designation-to-crb-701-for-the-treatment-of-relapsed-or-refractory-metastatic-cervical-cancer 2024-12-03T07:00:03-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/428/corbus-pharmaceuticals-to-present-at-the-7th-annual-evercore-healthconx-conference 2024-11-21T08:00:03-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/427/corbus-pharmaceuticals-to-present-at-the-jefferies-london-healthcare-conference 2024-11-12T08:00:52-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/426/corbus-pharmaceuticals-reports-3rd-quarter-2024-financial-results-and-provides-a-corporate-update 2024-11-07T07:00:08-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/425/corbus-pharmaceuticals-presents-new-crb-913-pre-clinical-data-at-obesity-week-2024 2024-11-04T07:00:34-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/424/corbus-pharmaceuticals-to-present-at-the-guggenheim-securities-healthcare-innovation-conference 2024-10-29T08:00:14-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/423/corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc-crb-701 2024-10-16T08:00:21-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/422/corbus-pharmaceuticals-to-participate-in-the-bmo-capital-markets-oncology-summit 2024-09-26T08:00:14-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/421/corbus-pharmaceuticals-to-present-at-the-2024-cantor-global-health-conference 2024-09-05T08:00:01-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/420/corbus-pharmaceuticals-strengthens-board-of-directors-with-appointment-of-winston-kung 2024-08-20T08:00:04-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/419/corbus-pharmaceuticals-reports-second-quarter-2024-financial-results-and-provides-a-corporate-update 2024-08-06T08:00:04-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/418/corbus-pharmaceuticals-to-participate-in-upcoming-investor-conferences-in-august 2024-07-30T08:50:40-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/417/sys6002-crb-701-a-next-generation-nectin-4-targeting-antibody-drug-conjugate-continues-to-demonstrate-encouraging-safety-and-efficacy-observed-in-patients-with-nectin-4-positive-tumors-in-a-clinical-update-presented-at-asco-2024 2024-06-01T10:00:02-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/416/corbus-pharmaceuticals-to-present-at-the-45th-annual-goldman-sachs-global-healthcare-conference 2024-05-30T08:00:09-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/415/updated-phase-1-clinical-data-for-sys-6002-crb-701-to-be-presented-at-2024-asco-annual-meeting 2024-05-23T17:05:27-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/414/corbus-pharmaceuticals-to-participate-in-the-2024-rbc-capital-markets-global-healthcare-conference 2024-05-09T08:00:01-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/413/corbus-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-corporate-update 2024-05-07T08:00:05-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/412/corbus-pharmaceuticals-to-participate-in-the-btig-obesity-health-forum 2024-05-01T08:00:08-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/411/corbus-pharmaceuticals-announces-abstract-accepted-for-presentation-at-2024-asco-annual-meeting 2024-04-24T16:05:03-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/410/corbus-announces-dosing-of-first-patient-in-u-s-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc 2024-04-02T08:00:07-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/409/corbus-pharmaceuticals-reports-fourth-quarter-and-year-end-2023-financial-results-and-provides-corporate-update 2024-03-12T08:00:06-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/408/corbus-pharmaceuticals-to-participate-in-the-bmo-capital-markets-inaugural-obesity-summit 2024-03-06T08:00:10-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/407/corbus-pharmaceuticals-appoints-dr-dominic-smethurst-as-chief-medical-officer 2024-02-28T08:00:10-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/406/corbus-pharmaceuticals-to-present-at-the-oppenheimer-34th-annual-healthcare-life-sciences-conference 2024-02-06T09:50:37-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/405/corbus-pharmaceuticals-announces-closing-of-94-5-million-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares 2024-02-02T16:01:12-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/404/corbus-pharmaceuticals-announces-pricing-of-public-offering 2024-01-31T09:19:42-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/403/corbus-pharmaceuticals-announces-proposed-public-offering 2024-01-30T18:55:31-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/402/crb-701-sys6002-a-next-generation-nectin-4-targeting-antibody-drug-conjugate-demonstrates-encouraging-safety-and-efficacy-in-patients-with-nectin-4-positive-tumors-in-first-in-human-study-presented-at-asco-gu-2024 2024-01-26T07:30:08-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/401/phase-1-clinical-data-for-sys6002-crb-701-to-be-presented-at-2024-asco-gu 2024-01-23T08:00:06-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/400/corbus-pharmaceuticals-announces-fda-clearance-of-ind-application-for-its-anti-v8-monoclonal-antibody-crb-601 2024-01-09T08:00:06-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/399/corbus-pharmaceuticals-announces-abstract-accepted-for-presentation-at-2024-asco-gu 2023-12-18T08:00:03-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/398/corbus-pharmaceuticals-reports-third-quarter-2023-financial-results-and-provides-corporate-update 2023-11-07T08:00:39-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/397/corbus-pharmaceuticals-presents-results-of-two-pre-clinical-studies-on-itsanti-v8-monoclonal-antibody-crb-601-at-the-2023-sitc-annual-meeting 2023-11-02T08:00:06-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/396/corbus-pharmaceuticals-announces-publication-of-data-for-its-novel-cannabinoid-type-1-receptor-inverse-agonist-in-a-pre-clinical-model-of-obesity-along-with-presentations-at-obesity-week-2023 2023-10-17T11:13:17-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/395/corbus-pharmaceuticals-presents-the-first-pre-clinical-characterization-of-its-next-generation-nectin-4-adc-crb-701 2023-10-16T08:00:06-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/394/corbus-pharmaceuticals-to-host-virtual-meet-the-expert-series-session-2-on-crb-701-on-october-10-2023 2023-10-03T08:00:04-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/393/corbus-pharmaceuticals-to-present-latest-pre-clinical-data-on-its-anti-avb8-monoclonal-antibody-crb-601-at-the-2023-sitc-annual-meeting 2023-09-27T09:05:05-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/392/corbus-pharmaceuticals-to-present-pre-clinical-data-characterizing-its-crb-701-nectin-4-adc-at-the-at-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics 2023-09-19T08:00:21-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/391/corbus-pharmaceuticals-reports-second-quarter-2023-financial-results-and-provides-corporate-update 2023-08-08T08:00:20-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/390/corbus-pharmaceuticals-to-present-at-the-btig-virtual-biotechnology-conference 2023-07-31T08:00:12-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/389/corbus-pharmaceuticals-set-to-join-russell-microcap-index 2023-06-26T08:00:19-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/388/corbus-pharmaceuticals-to-participate-in-the-2023-jefferies-healthcare-conference 2023-05-31T08:00:24-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/387/corbus-pharmaceuticals-reports-first-quarter-2023-financial-results-and-provides-corporate-update 2023-05-09T08:00:18-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/386/corbus-pharmaceuticals-to-present-latest-pre-clinical-data-on-crb-601-av8-blocking-antibody-at-the-new-york-academy-of-sciences-frontiers-in-cancer-immunotherapy-meeting 2023-05-01T08:00:22-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/384/corbus-pharmaceuticals-hosting-virtual-meet-the-expert-series-blocking-tgf-with-crb-601--a-new-play-for-an-old-target 2023-04-18T08:00:29-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/383/corbus-pharmaceuticals-presents-latest-pre-clinical-data-on-crb-601-at-the-2023-american-association-for-cancer-research-annual-meeting 2023-04-17T08:30:09-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/382/corbus-pharmaceuticals-data-on-crb-601-av8-blocking-antibody-accepted-for-presentation-at-the-america-association-for-cancer-research-annual-meeting 2023-03-14T16:35:04-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/381/corbus-pharmaceuticals-reports-fourth-quarter-2022-and-year-end-financial-results-and-provides-corporate-update 2023-03-07T08:00:20-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/380/corbus-pharmaceuticals-expands-board-of-directors-with-appointment-of-yong-ben-m-d-mba 2023-03-06T08:00:10-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/379/corbus-pharmaceuticals-to-present-at-the-oppenheimer-33rd-annual-healthcare-conference 2023-03-02T08:00:14-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/378/corbus-pharmaceuticals-expands-oncology-pipeline-with-the-addition-of-a-clinical-stage-nectin-4-targeting-antibody-drug-conjugate-adc 2023-02-13T06:55:07-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/377/corbus-presents-latest-preclinical-data-for-crb-601-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting 2022-11-10T09:05:05-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/376/corbus-pharmaceuticals-reports-third-quarter-2022-financial-results-and-provides-corporate-update 2022-11-08T08:05:05-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/375/corbus-pharmaceuticals-to-present-pre-clinical-data-for-crb-601-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting 2022-10-14T08:05:03-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/374/corbus-pharmaceuticals-appoints-anne-altmeyer-phd-to-board-of-directors 2022-09-26T08:05:03-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/373/corbus-presents-first-pre-clinical-data-for-crb-913-at-the-european-association-for-the-study-of-diabetes-2022-annual-conference 2022-09-22T08:00:11-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/372/corbus-pharmaceuticals-to-present-virtually-at-the-h-c-wainwright-24th-annual-global-investment-conference 2022-09-12T07:00:16-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/371/corbus-pharmaceuticals-reports-second-quarter-2022-financial-results-and-provides-corporate-update 2022-11-07T10:28:05-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/370/corbus-presents-latest-preclinical-data-for-crb-601-at-the-new-york-academy-of-sciences-frontiers-in-cancer-immunotherapy-conference 2022-05-11T08:00:19-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/369/corbus-pharmaceuticals-reports-first-quarter-2022-financial-results-and-provides-corporate-update 2022-05-10T08:00:19-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/368/corbus-presents-first-preclinical-data-for-crb-601-at-the-american-association-for-cancer-research-aacr-annual-meeting 2022-04-08T13:24:38-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/367/corbus-pharmaceuticals-to-present-at-the-oppenheimer-32nd-annual-healthcare-conference 2022-03-15T15:11:56-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/366/corbus-pharmaceuticals-reports-fourth-quarter-and-year-end-2021-financial-results-and-provides-corporate-updates 2022-03-08T08:05:05-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/365/corbus-pharmaceuticals-appoints-rachael-brake-ph-d-as-chief-scientific-officer 2021-12-07T08:05:04-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/364/corbus-pharmaceuticals-reports-third-quarter-2021-financial-results-and-provides-corporate-updates 2021-11-12T08:05:02-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/363/corbus-pharmaceuticals-to-present-at-the-jefferies-london-healthcare-conference 2021-11-11T08:05:02-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/362/corbus-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-corporate-updates 2021-08-12T08:05:02-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/361/corbus-pharmaceuticals-announces-topline-results-from-determine-phase-3-study-of-lenabasum-for-treatment-of-dermatomyositis 2021-06-24T08:05:02-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/360/corbus-pharmaceuticals-licenses-two-integrin-targeting-mabs-further-expanding-pipeline-into-cancer-and-fibrotic-diseases 2021-06-01T07:05:01-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/359/corbus-pharmaceuticals-announces-publication-of-two-abstracts-at-eular-2021-virtual-congress 2021-05-25T08:05:01-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/358/corbus-pharmaceuticals-announces-adjournment-of-annual-meeting 2021-05-19T16:52:11-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/357/corbus-pharmaceuticals-reports-first-quarter-2021-financial-results-and-provides-corporate-updates 2021-05-13T08:05:02-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/356/corbus-pharmaceuticals-to-present-at-three-upcoming-investor-conferences 2021-05-11T08:05:01-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/355/corbus-pharmaceuticals-announces-completion-of-enrollment-in-nih-sponsored-phase-2-study-of-lenabasum-for-treatment-of-systemic-lupus-erythematosus-sle 2021-04-20T08:36:25-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/354/corbus-pharmaceuticals-reports-last-subject-visit-in-determine-phase-3-study-of-lenabasum-for-treatment-of-dermatomyositis 2021-03-30T08:05:00-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/353/corbus-pharmaceuticals-reports-fourth-quarter-and-year-end-2020-financial-results 2021-03-22T10:24:23-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/352/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences 2021-03-09T08:05:01-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/351/corbus-pharmaceuticals-to-report-fourth-quarter-and-year-end-2020-results-on-march-15-2021 2021-03-08T08:05:01-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/350/corbus-pharmaceuticals-announces-presentations-at-the-new-york-academy-of-sciences-webinar-on-targeting-the-endocannabinoid-system-to-treat-human-diseases 2021-01-20T09:39:39-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/349/corbus-pharmaceuticals-to-present-at-the-jefferies-virtual-london-healthcare-conference 2020-11-12T08:05:00-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/348/corbus-pharmaceuticals-reports-third-quarter-financial-results-and-provides-corporate-updates 2020-11-10T07:05:02-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/347/corbus-pharmaceuticals-presents-additional-data-from-resolve-1-study-in-systemic-sclerosis 2020-11-09T08:05:02-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/346/corbus-pharmaceuticals-to-report-third-quarter-results-on-november-10-2020 2020-11-03T08:05:00-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/345/corbus-pharmaceuticals-announces-presentation-of-data-from-its-phase-2b-study-in-cystic-fibrosis-at-nacfc-2020 2020-10-23T09:08:44-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/344/corbus-pharmaceuticals-announces-three-lenabasum-abstracts-to-be-presented-at-acr-convergence-2020 2020-10-21T08:05:03-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/343/corbus-pharmaceuticals-announces-corporate-restructuring-and-pipeline-portfolio-updates 2020-10-08T08:05:04-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/342/corbus-pharmaceuticals-announces-phase-2b-study-of-lenabasum-for-treatment-of-cystic-fibrosis-did-not-meet-primary-endpoint 2020-10-06T07:05:03-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/341/corbus-pharmaceuticals-announces-topline-results-from-resolve-1-phase-3-study-of-lenabasum-for-treatment-of-systemic-sclerosis 2020-09-08T07:05:04-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/340/corbus-pharmaceuticals-reports-second-quarter-financial-results-and-corporate-updates 2020-08-06T07:05:03-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/339/corbus-pharmaceuticals-completes-enrollment-in-determine-phase-3-study-of-lenabasum-for-treatment-of-dermatomyositis 2020-08-10T10:33:02-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/338/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences 2020-08-03T08:05:03-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/337/corbus-pharmaceuticals-to-report-second-quarter-results-on-august-6-2020 2020-07-30T08:05:03-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/336/corbus-pharmaceuticals-strengthens-balance-sheet-with-up-to-121-million-in-new-capital 2020-07-29T08:05:03-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/335/corbus-pharmaceuticals-appoints-george-golumbeski-ph-d-to-board-of-directors 2020-07-08T08:05:03-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/334/corbus-pharmaceuticals-presents-data-demonstrating-acr-criss-score-reflects-patient-reported-outcomes-at-6th-systemic-sclerosis-world-e-congress 2020-06-29T08:05:02-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/333/corbus-pharmaceuticals-reports-last-subject-visit-in-phase-2b-study-of-lenabasum-for-treatment-of-cystic-fibrosis 2020-06-22T08:05:02-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/332/corbus-pharmaceuticals-announces-publication-of-phase-2b-cystic-fibrosis-study-patient-demographics-and-baseline-disease-characteristics-in-the-journal-of-cystic-fibrosis 2020-06-01T08:05:03-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/331/corbus-pharmaceuticals-reports-last-subject-visit-in-resolve-1-phase-3-study-of-lenabasum-for-treatment-of-systemic-sclerosis 2020-05-27T08:05:03-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/330/corbus-pharmaceuticals-announces-publication-of-two-abstracts-at-eular-2020-e-congress 2020-05-22T08:05:04-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/329/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences 2020-05-15T08:05:02-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/328/corbus-pharmaceuticals-reports-first-quarter-financial-results-and-corporate-updates 2020-05-11T07:05:03-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/327/corbus-pharmaceuticals-to-report-first-quarter-results-on-may-11-2020 2020-05-04T08:05:03-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/326/corbus-announces-publication-of-lenabasum-systemic-sclerosis-double-blind-placebo-controlled-phase-2-clinical-trial-results-in-arthritis-rheumatology 2020-04-29T08:21:20-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/325/corbus-pharmaceuticals-reports-fourth-quarter-and-year-end-2019-financial-results 2020-03-25T23:31:29-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/324/corbus-pharmaceuticals-announces-changes-to-its-board-and-appointment-of-pete-salzmann-m-d-as-independent-director 2020-03-10T08:05:05-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/323/corbus-pharmaceuticals-to-report-fourth-quarter-and-year-end-2019-results-on-march-12-2020 2020-03-05T08:05:03-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/322/corbus-pharmaceuticals-announces-closing-of-46-million-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares 2020-02-11T16:01:05-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/321/corbus-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock 2020-02-07T09:02:11-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/320/corbus-pharmaceuticals-announces-proposed-public-offering-of-common-stock 2020-02-06T16:00:57-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/319/corbus-pharmaceuticals-to-host-expert-symposium-on-the-therapeutic-potential-of-targeting-the-endocannabinoid-system 2019-12-12T17:25:05-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/318/corbus-pharmaceuticals-completes-enrollment-of-phase-2b-study-of-lenabasum-for-treatment-of-cystic-fibrosis 2019-11-18T08:17:05-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/317/corbus-pharmaceuticals-to-present-at-the-jefferies-2019-global-healthcare-conference-in-london 2019-11-12T08:05:00-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/316/corbus-pharmaceuticals-updates-data-from-lenabasum-open-label-extension-studies-in-systemic-sclerosis-and-dermatomyositis-at-2019-acr-annual-meeting 2019-11-11T15:02:20-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/315/corbus-pharmaceuticals-reports-2019-third-quarter-financial-results-and-provides-clinical-and-corporate-updates 2019-11-07T07:05:02-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/314/corbus-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-third-quarter-2019-operational-and-financial-results-on-november-7-2019 2019-11-04T08:05:01-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/313/corbus-pharmaceuticals-announces-presentation-of-three-abstracts-and-new-lenabasum-data-at-2019-acr-annual-meeting 2019-10-07T21:50:28-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/312/corbus-pharmaceuticals-reports-2019-second-quarter-financial-results-and-provides-clinical-and-corporate-updates 2019-08-08T07:05:06-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/311/corbus-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-second-quarter-2019-operational-and-financial-results-on-august-8-2019 2019-08-01T08:05:02-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/310/corbus-pharmaceuticals-to-host-2019-rd-day-in-new-york-city 2019-06-17T08:05:33-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/309/lenabasum-open-label-extension-data-to-be-presented-at-eular-2019-continue-to-show-a-favorable-safety-profile-and-improvement-in-efficacy-outcomes-in-systemic-sclerosis-and-dermatomyositis-phase-2-studies 2019-06-12T08:18:10-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/307/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences-in-june 2019-05-29T08:05:14-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/306/corbus-pharmaceuticals-announces-presentation-of-six-abstracts-at-eular-2019-annual-meeting 2019-05-28T08:05:13-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/305/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences-in-may 2019-05-15T08:05:04-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/304/corbus-pharmaceuticals-reports-2019-first-quarter-financial-results-and-provides-clinical-updates 2019-05-09T07:14:57-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/308/corbus-pharmaceuticals-completes-enrollment-of-resolve-1-phase-3-study-of-lenabasum-for-treatment-of-systemic-sclerosis 2019-06-03T18:07:11-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/303/corbus-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-first-quarter-2019-operational-and-financial-results-on-may-9-2019 2019-05-01T08:05:06-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/302/corbus-pharmaceuticals-announces-change-of-primary-endpoint-in-ongoing-resolve-1-phase-3-study-in-systemic-sclerosis-in-u-s-to-acr-criss-from-mrss-following-meeting-with-fda 2019-04-18T08:05:04-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/301/corbus-pharmaceuticals-appoints-rachelle-jacques-to-board-of-directors 2019-04-08T08:05:06-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/300/corbus-pharmaceuticals-provides-management-team-updates 2019-03-28T08:05:04-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/299/corbus-pharmaceuticals-reports-fourth-quarter-and-full-year-2018-financial-results-and-provides-clinical-updates 2019-03-18T14:51:47-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/298/corbus-pharmaceuticals-to-present-at-the-oppenheimer-29th-annual-healthcare-conference 2019-03-11T09:56:57-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/297/corbus-pharmaceuticals-to-announce-full-year-2018-operational-and-financial-results-on-march-12-2019 2019-03-07T08:00:28-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/296/corbus-pharmaceuticals-announces-appointment-of-craig-millian-as-chief-commercial-officer 2019-03-04T09:15:03-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/295/corbus-pharmaceuticals-announces-closing-of-40-million-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares 2019-01-30T07:30:08-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/294/corbus-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock 2019-01-25T09:01:04-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/293/corbus-pharmaceuticals-announces-proposed-public-offering-of-common-stock 2019-01-24T16:01:05-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/292/corbus-pharmaceuticals-announces-strategic-collaboration-with-kaken-pharmaceutical-co-ltd-to-develop-and-commercialize-lenabasum-in-japan-for-systemic-sclerosis-and-dermatomyositis 2019-01-03T10:01:04-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/291/corbus-pharmaceuticals-announces-issuance-of-composition-of-matter-patent-related-to-lenabasum 2018-12-18T08:46:10-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/290/corbus-pharmaceuticals-initiates-determine-phase-3-study-in-dermatomyositis 2018-12-17T07:00:22-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/289/corbus-pharmaceuticals-reports-third-quarter-2018-financial-results-and-provides-business-update 2019-04-08T15:37:00-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/288/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences-in-november 2018-11-06T08:00:05-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/287/corbus-pharmaceuticals-to-announce-third-quarter-2018-operational-and-financial-results-on-november-8-2018 2018-11-05T08:00:25-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/286/corbus-pharmaceuticals-presents-lenabasum-long-term-open-label-clinical-data-showing-maintenance-of-favorable-safety-profile-and-further-improvement-in-multiple-efficacy-endpoints-in-systemic-sclerosis-and-dermatomyositis-phase-2-studies 2018-10-22T08:00:42-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/285/corbus-pharmaceuticals-presents-data-on-impact-of-lenabasum-on-inflammation-of-airway-macrophages-from-cystic-fibrosis-lungs-at-the-2018-north-american-cystic-fibrosis-conference 2018-10-18T16:05:04-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/284/corbus-pharmaceuticals-announces-patent-issuance-covering-use-of-lenabasum-for-the-treatment-of-fibrotic-diseases-providing-exclusivity-to-2034 2018-10-03T09:00:18-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/283/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences-in-october 2018-09-26T08:00:16-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/282/corbus-pharmaceuticals-expands-target-indications-by-adding-more-than-600-compounds-focused-on-the-endocannabinoid-system-from-jenrin-discovery-includes-crb-4001-with-planned-nih-supported-phase-2-study 2018-09-20T07:00:12-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/281/corbus-pharmaceuticals-receives-orphan-designation-for-lenabasum-for-the-treatment-of-dermatomyositis-in-the-european-union 2018-09-18T08:05:08-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/280/corbus-pharmaceuticals-announces-presentation-of-three-abstracts-and-new-lenabasum-data-at-2018-acr-annual-meeting 2018-09-14T08:05:04-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/279/corbus-pharmaceuticals-to-present-at-the-annual-b-riley-fbr-healthcare-conference 2018-08-23T08:05:04-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/278/corbus-pharmaceuticals-reports-2018-second-quarter-financial-results-and-provides-business-update 2018-08-08T09:00:28-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/277/corbus-pharmaceuticals-to-commence-phase-3-study-of-lenabasum-for-the-treatment-of-rare-autoimmune-disease-dermatomyositis 2018-07-25T09:20:03-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/276/corbus-pharmaceuticals-receives-fda-orphan-drug-designation-for-lenabasum-for-the-treatment-of-dermatomyositis 2018-07-20T09:20:02-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/275/corbus-pharmaceuticals-announces-resolution-of-inflammation-infection-and-tissue-regeneration-conference 2018-06-21T08:00:15-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/274/corbus-pharmaceuticals-to-present-at-the-jmp-securities-life-science-conference 2018-06-14T08:25:03-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/273/corbus-pharmaceuticals-presents-1-year-systemic-sclerosis-and-6-month-dermatomyositis-data-from-open-label-extension-of-phase-2-lenabasum-studies-at-eular-2018 2018-06-13T09:29:03-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/272/corbus-pharmaceuticals-appoints-former-director-of-fda-office-of-new-drugs-john-k-jenkins-md-to-board-of-directors 2018-06-06T07:05:02-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/271/corbus-pharmaceuticals-to-present-at-the-jefferies-2018-global-healthcare-conference 2018-05-24T08:00:07-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/270/corbus-pharmaceuticals-adds-two-key-executives-to-lead-its-regulatory-and-cmc-operations 2018-05-22T08:00:08-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/269/corbus-pharmaceuticals-announces-acceptance-of-three-abstracts-for-presentation-at-eular-2018-annual-meeting 2018-05-15T13:21:07-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/268/corbus-pharmaceuticals-reports-2018-first-quarter-financial-results-and-provides-business-update 2018-05-10T08:00:10-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/267/corbus-pharmaceuticals-to-present-at-the-deutsche-bank-43rd-annual-health-care-conference 2018-04-26T08:00:07-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/266/corbus-pharmaceuticals-reports-2017-financial-results-and-provides-clinical-update 2018-03-12T07:06:07-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/265/corbus-pharmaceuticals-to-present-at-the-cowen-co-38th-annual-health-care-conference 2018-03-05T09:06:29-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/264/corbus-pharmaceuticals-announces-publication-demonstrating-lenabasum-as-first-drug-to-stimulate-resolution-of-innate-immune-responses-in-a-clinical-model 2018-02-15T07:00:01-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/263/corbus-pharmaceuticals-to-present-at-the-2018-rbc-capital-markets-global-healthcare-conference 2018-02-14T07:00:00-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/262/corbus-pharmaceuticals-to-present-at-the-7th-annual-leerink-partners-global-healthcare-conference 2018-02-06T08:00:00-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/261/corbus-pharmaceuticals-receives-25-million-development-award-from-the-cystic-fibrosis-foundation-to-support-phase-2b-clinical-study-of-lenabasum 2018-01-30T07:05:01-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/260/corbus-pharmaceuticals-announces-agreement-with-fda-on-phase-2b-cystic-fibrosis-study-design-with-pulmonary-exacerbations-as-sole-primary-endpoint 2018-01-29T16:05:02-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/259/corbus-pharmaceuticals-announces-initiation-of-phase-2-study-of-anabasum-for-treatment-of-systemic-lupus-erythematosus 2019-05-06T18:16:19-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/258/corbus-pharmaceuticals-initiates-resolve-1-phase-3-study-in-systemic-sclerosis 2019-05-06T18:16:01-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/257/corbus-pharmaceuticals-holdings-inc-announces-exercise-of-option-to-purchase-additional-shares-in-public-offering 2017-11-27T16:05:00-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/256/corbus-pharmaceuticals-expands-intellectual-property-portfolio-with-patent-issuance-covering-the-use-of-anabasum-for-the-treatment-of-rare-fibrotic-diseases 2019-05-06T18:15:37-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/255/corbus-pharmaceuticals-to-present-at-the-29th-annual-piper-jaffray-healthcare-conference 2017-11-15T08:00:01-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/254/corbus-pharmaceuticals-to-present-at-the-stifel-2017-healthcare-conference 2017-11-09T07:30:05-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/253/corbus-pharmaceuticals-reports-2017-third-quarter-financial-results-and-highlights-recent-corporate-and-clinical-advancements 2017-11-08T08:05:01-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/252/corbus-pharmaceuticals-reports-significant-improvement-in-mrss-and-other-clinical-outcomes-at-28-weeks-in-systemic-sclerosis-open-label-extension-of-phase-2-study 2017-11-06T08:30:01-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/251/corbus-pharmaceuticals-announces-new-patent-issuance-covering-the-use-of-anabasum-for-the-treatment-of-inflammatory-diseases 2017-10-31T07:05:01-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/250/corbus-pharmaceuticals-holdings-inc-prices-underwritten-public-offering-of-common-stock 2017-10-24T09:06:58-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/249/corbus-pharmaceuticals-holdings-inc-announces-proposed-public-offering-of-common-stock 2017-10-23T16:01:00-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/248/corbus-pharmaceuticals-reports-positive-topline-results-from-phase-2-study-in-rare-autoimmune-disease-dermatomyositis 2017-10-19T07:30:02-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/247/corbus-pharmaceuticals-appoints-paris-panayiotopoulos-to-its-board-of-directors 2017-10-17T07:30:02-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/246/corbus-pharmaceuticals-announces-presentation-of-three-abstracts-at-the-2017-north-american-cystic-fibrosis-conference 2017-09-25T07:00:01-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/245/corbus-pharmaceuticals-announces-presentation-of-six-abstracts-and-new-anabasum-data-at-2017-acr-annual-meeting 2017-09-20T08:00:04-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/244/corbus-pharmaceuticals-to-present-at-the-cantor-fitzgerald-global-healthcare-conference 2017-09-14T08:00:01-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/243/corbus-pharmaceuticals-to-host-fireside-chat-on-dermatomyositis-with-expert-physician-and-researcher-victoria-werth-md 2017-08-31T08:05:00-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/242/corbus-pharmaceuticals-reports-2017-second-quarter-financial-results-and-provides-business-update 2017-08-09T08:49:46-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/241/corbus-pharmaceuticals-to-present-new-data-from-systemic-sclerosis-phase-2-study-of-anabasum-at-the-15th-international-workshop-on-scleroderma-research 2017-10-20T15:11:42-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/240/corbus-pharmaceuticals-announces-inclusion-in-russell-3000r-index 2017-06-26T08:00:06-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/239/corbus-pharmaceuticals-presented-data-from-phase-2-study-of-anabasum-for-the-treatment-of-systemic-sclerosis-at-the-eular-2017-annual-meeting 2017-10-20T15:11:42-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/238/corbus-pharmaceuticals-to-present-data-from-phase-2-study-of-anabasum-at-the-european-cystic-fibrosis-society-2017-conference 2017-10-20T15:11:42-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/237/corbus-pharmaceuticals-to-present-at-the-2017-jefferies-global-healthcare-conference 2017-06-01T07:30:01-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/236/corbus-pharmaceuticals-announces-last-subject-enrolled-in-phase-2-study-of-anabasum-for-the-treatment-of-skin-predominant-dermatomyositis 2017-05-11T08:00:01-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/235/corbus-pharmaceuticals-reports-2017-first-quarter-financial-results-and-provides-business-update 2017-05-09T09:00:17-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/234/corbus-pharmaceuticals-to-commence-single-phase-3-study-of-anabasum-for-treatment-of-systemic-sclerosis-following-guidance-received-from-successful-end-of-phase-2-meeting-with-fda 2017-04-05T08:30:03-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/233/corbus-pharmaceuticals-reports-positive-topline-data-demonstrating-anabasum-reduces-acute-pulmonary-exacerbations-and-multiple-inflammatory-biomarkers-in-phase-2-study-in-patients-with-cystic-fibrosis 2017-03-30T06:00:01-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/232/corbus-pharmaceuticals-reports-2016-financial-results-and-provides-2017-business-update 2017-03-09T07:00:06-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/231/corbus-pharmaceuticals-to-present-gene-expression-data-from-recent-phase-2-systemic-sclerosis-study-demonstrating-jbt-101-inhibits-inflammation-and-fibrosis-pathways 2017-03-08T08:00:05-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/230/corbus-pharmaceuticals-completes-27-2-million-registered-direct-offering 2017-03-03T07:30:00-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/229/corbus-pharmaceuticals-to-present-at-the-cowen-and-company-37th-annual-health-care-conference 2017-03-01T07:30:04-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/228/corbus-pharmaceuticals-announces-27-2-million-registered-direct-offering 2017-02-28T09:00:03-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/227/corbus-pharmaceuticals-announces-preclinical-data-demonstrating-jbt-101-reduces-inflammation-in-alveolar-macrophages-from-cystic-fibrosis-patients 2017-02-23T08:05:00-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/226/corbus-pharmaceuticals-to-host-research-and-development-day-on-march-13-2017 2017-02-21T07:30:01-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/225/corbus-pharmaceuticals-receives-orphan-designation-for-jbt-101-for-the-treatment-of-systemic-sclerosis-in-the-european-union 2017-01-17T07:30:01-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/224/corbus-pharmaceuticals-announces-completion-of-phase-2-study-of-jbt-101-resunab-for-the-treatment-of-cystic-fibrosis 2016-12-29T07:30:01-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/223/corbus-pharmaceuticals-announces-nasdaq-closing-bell-ceremony 2016-12-05T07:00:05-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/222/corbus-pharmaceuticals-commences-one-year-open-label-extension-to-its-ongoing-phase-2-study-of-resunab-jbt-101-for-skin-predominant-dermatomyositis 2016-11-29T07:30:03-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/221/corbus-pharmaceuticals-reports-positive-topline-results-showing-clear-signal-of-clinical-benefit-with-resunab-jbt-101-in-phase-2-study-in-systemic-sclerosis 2016-11-14T06:30:00-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/220/corbus-pharmaceuticals-reports-2016-third-quarter-financial-results-and-provides-business-update 2016-11-10T16:05:32-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/219/corbus-pharmaceuticals-receives-orphan-designation-for-resunab-for-the-treatment-of-cystic-fibrosis-in-the-european-union 2016-10-18T07:00:01-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/218/corbus-pharmaceuticals-announces-completion-of-phase-2-study-of-resunab-for-systemic-sclerosis 2016-10-13T07:30:00-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/217/corbus-announces-data-on-effects-of-resunab-jbt-101-in-a-clinical-research-model-of-resolution-of-inflammation 2017-10-20T15:11:41-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/216/corbus-pharmaceuticals-to-present-at-the-jefferies-cystic-fibrosis-summit 2016-09-19T08:20:32-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/215/corbus-pharmaceuticals-announces-last-subject-enrolled-in-phase-2-study-of-resunab-for-the-treatment-of-cystic-fibrosis 2017-10-20T17:34:19-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/214/corbus-pharmaceuticals-reports-2016-second-quarter-financial-results-and-provides-business-update 2016-08-15T07:30:04-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/213/corbus-pharmaceuticals-to-present-at-the-cantor-fitzgerald-2nd-annual-healthcare-conference-on-july-12-2016 2016-07-06T07:30:01-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/212/corbus-pharmaceuticals-to-present-at-the-jmp-securities-life-sciences-conference-on-june-22-2016 2016-06-17T07:00:01-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/211/corbus-pharmaceuticals-announces-last-patient-enrolled-in-phase-2-study-of-resunab-for-systemic-sclerosis 2016-06-16T07:00:02-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/210/corbus-pharmaceuticals-completes-15-million-registered-direct-offering 2016-06-15T07:05:04-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/209/corbus-pharmaceuticals-announces-15-million-registered-direct-offering 2016-06-10T09:25:01-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/208/corbus-pharmaceuticals-reports-2016-first-quarter-financial-results-and-provides-business-update 2016-05-16T08:13:12-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/207/corbus-pharmaceuticals-receives-fda-approval-for-open-label-extension-to-its-phase-2-trial-of-resunab-for-systemic-sclerosis 2016-04-12T11:01:05-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/206/corbus-pharmaceuticals-announces-addition-of-phase-2-clinical-protocol-for-resunab-treatment-of-systemic-lupus-erythematosus-to-fda-ind 2016-03-31T07:30:00-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/205/corbus-pharmaceuticals-reports-2015-financial-results-and-provides-2016-business-update 2016-03-29T07:30:09-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/204/corbus-pharmaceuticals-expands-clinical-development-of-resunabtm-with-phase-2-trial-for-the-treatment-of-systemic-lupus-erythematosus 2016-03-07T07:35:00-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/203/corbus-pharmaceuticals-to-present-at-the-18th-annual-bio-ceo-investor-conference-on-february-9-2016 2016-02-01T07:05:00-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/202/corbus-pharmaceuticals-to-present-at-biotech-showcasetm-on-january-12-2016 2016-01-05T07:05:01-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/201/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences-in-december-2015 2015-11-23T07:05:00-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/200/corbus-pharmaceuticals-reports-2015-third-quarter-financial-results 2015-11-11T07:05:04-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/199/corbus-pharmaceuticals-announces-fda-orphan-drug-designation-and-fast-track-status-of-resunabtm-for-the-treatment-of-cystic-fibrosis 2015-10-20T08:05:00-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/198/corbus-pharmaceuticals-announces-first-patient-dosed-in-phase-2-study-of-resunabtm-for-treatment-of-cystic-fibrosis 2015-10-15T07:30:01-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/197/corbus-pharmaceuticals-to-present-at-the-14th-annual-bio-investor-forum 2018-09-19T11:32:34-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/196/corbus-pharmaceuticals-announces-first-patient-dosed-in-phase-2-study-of-resunab-for-systemic-sclerosis 2017-10-20T15:11:40-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/195/corbus-pharmaceuticals-to-present-additional-data-on-the-effects-of-resunabtm-in-the-treatment-of-pulmonary-infection-and-inflammation-in-pre-clinical-models-of-cystic-fibrosis 2017-10-20T15:11:40-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/194/corbus-pharmaceuticals-commences-patient-enrollment-in-phase-2-clinical-study-of-resunabtm-for-the-treatment-of-cystic-fibrosis 2017-10-20T15:11:39-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/193/corbus-pharmaceuticals-commences-patient-enrollment-in-phase-2-clinical-study-of-resunabtm-for-the-treatment-of-systemic-sclerosis 2017-10-20T15:11:39-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/192/corbus-pharmaceuticals-successfully-completes-warrant-call----raises-11-3-mm-in-total-from-100-exercise-of-callable-warrants 2017-10-20T15:11:39-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/191/corbus-pharmaceuticals-investigational-drug-resunabtm-granted-fast-track-status-by-the-u-s-fda-for-the-treatment-of-systemic-sclerosis 2017-10-20T15:11:38-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/190/corbus-pharmaceuticals-reports-2015-second-quarter-financial-results-and-provides-business-update 2015-08-13T07:05:01-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/189/corbus-pharmaceuticals-to-present-at-the-canaccord-genuity-growth-conference-on-august-13-2015 2017-10-20T15:11:38-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/188/corbus-pharmaceuticals-announces-call-notice-for-exercise-of-warrants 2015-07-27T16:30:03-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/187/corbus-pharmaceuticals-announces-dosing-of-first-patient-in-phase-2-clinical-trial-of-resunabtm-for-the-treatment-of-dermatomyositis 2015-07-13T08:35:11-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/186/corbus-pharmaceuticals-to-present-at-the-jmp-securities-life-sciences-conference-on-june-23-2015 2015-06-17T07:05:01-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/185/corbus-pharmaceuticals-announces-inclusion-in-russell-microcapr-index 2015-06-16T07:05:00-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/184/corbus-pharmaceuticals-announces-fda-orphan-drug-designation-for-resunabtm-for-the-treatment-of-systemic-sclerosis-scleroderma 2015-06-12T08:12:00-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/183/corbus-pharmaceuticals-expands-clinical-development-of-resunabtm-with-a-phase-2-trial-for-the-treatment-of-rare-disease-dermatomyositis 2015-12-16T14:31:06-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/182/corbus-pharmaceuticals-announces-presentation-of-positive-data-on-resunabtm-in-pre-clinical-models-of-cystic-fibrosis-at-the-2015-cystic-fibrosis-foundation-research-conference 2015-06-01T08:05:00-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/181/corbus-pharmaceuticals-receives-fda-clearance-to-initiate-phase-2-clinical-study-of-resunab-for-the-treatment-of-cystic-fibrosis 2015-05-18T14:55:48-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/180/corbus-pharmaceuticals-appoints-charles-n-serhan-ph-d-to-scientific-advisory-board 2015-05-14T08:05:01-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/179/corbus-pharmaceuticals-reports-2015-first-quarter-financial-results-and-provides-business-update 2015-05-13T07:05:01-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/178/corbus-pharmaceuticals-to-present-at-the-cystic-fibrosis-workshop-hosted-by-jmp-securities-on-may-8-2015 2015-05-04T07:09:26-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/177/corbus-pharmaceuticals-receives-5-million-development-award-from-cystic-fibrosis-foundation-therapeutics-to-advance-resunab-clinical-program 2015-05-18T14:56:05-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/176/corbus-pharmaceuticals-announces-initiation-of-trading-on-the-nasdaq-capital-market 2015-04-16T07:38:48-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/175/corbus-pharmaceuticals-announces-uplisting-to-the-nasdaq-capital-market 2015-04-13T15:08:35-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/174/corbus-pharmaceuticals-announces-presentation-of-positive-data-on-anti-fibrotic-effects-of-resunab-in-a-preclinical-model-of-lung-fibrosis-at-the-experimental-biology-2015-scientific-conference 2015-05-18T14:56:18-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/164/corbus-pharmaceuticals-ind-receives-clearance-from-fda-to-initiate-phase-2-trials-in-scleroderma-with-its-novel-specialized-pro-resolving-mediator-drug-resunab 2015-05-18T14:56:29-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/154/corbus-pharmaceuticals-observes-annual-rare-disease-day 2015-02-27T08:05:00-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/144/corbus-pharmaceuticals-to-present-at-the-leerink-global-healthcare-conference-on-february-11-2015 2015-02-11T07:35:00-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/134/corbus-pharmaceuticals-reports-2014-financial-results-and-provides-2015-business-update 2015-02-10T07:05:01-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/124/corbus-pharmaceuticals-to-present-at-the-17th-annual-bio-ceo-investor-conference-on-february-9-2015 2015-02-02T08:05:00-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/114/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences 2015-01-07T08:08:22-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/104/corbus-pharmaceuticals-to-present-at-the-oppenheimer-25th-annual-healthcare-conference-on-december-10-2014 2014-12-03T08:05:00-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/94/corbus-pharmaceuticals-to-present-at-virtualinvestorconferences-com-online-event-on-december-4-2014 2014-12-01T08:30:04-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/84/corbus-pharmaceuticals-reports-2014-third-quarter-results-and-business-update 2014-11-13T06:00:02-05:00 https://ir.corbuspharma.com/news-events/press-releases/detail/74/corbus-pharmaceuticals-commences-trading-on-otcqb-under-ticker-symbol-crbp 2014-10-28T08:03:39-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/64/corbus-pharmaceuticals-to-present-at-the-13th-annual-bio-investor-forum-in-san-francisco-on-wednesday-october-8-2014 2014-10-21T11:07:55-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/54/corbus-pharmaceuticals-to-present-at-the-leerink-partners-rare-disease-roundtable-in-new-york-on-wednesday-october-1-2014 2014-10-21T11:07:29-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/44/corbus-pharmaceuticals-to-present-at-two-investor-conferences-in-september 2014-10-21T11:06:55-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/34/corbus-pharmaceuticals-observes-world-scleroderma-day 2014-10-21T11:05:52-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/24/corbus-pharmaceuticals-to-present-at-the-2014-bio-international-convention 2014-10-21T11:05:12-04:00 https://ir.corbuspharma.com/news-events/press-releases/detail/14/corbus-pharmaceuticals-completes-10-3-million-private-placement 2014-10-21T11:04:29-04:00 https://ir.corbuspharma.com/news-events/events/detail/20260513-2026-annual-meeting-of-stockholders 2026-04-02T21:16:40-04:00 https://ir.corbuspharma.com/news-events/events/detail/20260225-oppenheimer-36th-annual-healthcare-life-sciences-conference 2026-02-12T08:29:36-05:00 https://ir.corbuspharma.com/news-events/events/detail/20260115-44th-annual-j-p-morgan-healthcare-conference 2026-01-05T07:32:45-05:00 https://ir.corbuspharma.com/news-events/events/detail/20251211-corbus-pharma-virtual-webinar-on-crb-913-for-the-treatment-of-obesity 2025-12-10T20:54:34-05:00 https://ir.corbuspharma.com/news-events/events/detail/20251202-evercores-8th-annual-healthcare-conference 2025-11-06T09:15:26-05:00 https://ir.corbuspharma.com/news-events/events/detail/20251118-jefferies-global-healthcare-conference 2025-11-06T09:14:49-05:00 https://ir.corbuspharma.com/news-events/events/detail/20251112-guggenheims-second-annual-healthcare-innovation-conference 2025-11-06T09:15:40-05:00 https://ir.corbuspharma.comhttps://lifescievents.com/event/vak208zhgo/ 2025-10-14T17:01:59-04:00 https://ir.corbuspharma.com/news-events/events/detail/20251017-european-society-for-medical-oncology-esmo-congress-2025 2025-07-30T08:24:50-04:00 https://ir.corbuspharma.com/sec-filings/all-sec-filings/content/0001193125-26-140398/0001193125-26-140398.pdf 2026-04-02T16:53:04-04:00 https://ir.corbuspharma.com/sec-filings/all-sec-filings/content/0001193125-26-140385/crbp_defa14a_2026_04_02.htm 2026-04-02T16:50:26-04:00 https://ir.corbuspharma.com/sec-filings/all-sec-filings/content/0001193125-26-140363/crbp-20260401.htm 2026-04-02T16:48:10-04:00 https://ir.corbuspharma.com/sec-filings/all-sec-filings/content/0001193125-26-124201/crbp_424b3_2026_03_20.htm 2026-03-25T16:31:34-04:00 https://ir.corbuspharma.com/sec-filings/all-sec-filings/content/9999999995-26-000891/primary_doc.html 2026-03-23T06:03:53-04:00 https://ir.corbuspharma.com/sec-filings/all-sec-filings/content/0001193125-26-102396/crbp-20260311.htm 2026-03-11T17:22:24-04:00 https://ir.corbuspharma.com/sec-filings/all-sec-filings/content/0001193125-26-098530/crbp-20251231.htm 2026-03-09T16:19:24-04:00 https://ir.corbuspharma.com/sec-filings/all-sec-filings/content/0001193125-26-097582/crbp-20260309.htm 2026-03-09T07:44:17-04:00 https://ir.corbuspharma.com/sec-filings/all-sec-filings/content/0001193125-26-091647/ownership.html 2026-03-04T16:31:14-05:00 https://ir.corbuspharma.com/sec-filings/all-sec-filings/content/0001972481-26-000071/primary_doc.html 2026-03-02T16:13:40-05:00 https://ir.corbuspharma.com/sitemap https://ir.corbuspharma.com/accessibility-statement